Indian Alliance For Pfizer/BioNTech’s COVID-19 Vaccine?
COVAX Supplies Being Discussed
Executive Summary
Pfizer is unlikely to tie up with Indian companies soon for manufacture of its COVID-19 vaccine as it has built capacity for the first phase. However, as discussions to supply to the COVAX facility and developing countries progress, it could evaluate such opportunities later.
You may also be interested in...
How Pfizer Crafted Its Own ‘Operation Warp Speed’ For The COVID-19 Vaccine
It’s counter-intuitive, but not signing a commercial contract with BioNTech and refusing US federal funding were two of several moves Pfizer made to speed up development of its COVID-19 vaccine, CEO Albert Bourla says. Now it’s looking to supply low- and middle-income countries.
Coronavirus Update: Bharat's Vaccine Looks Good In New Analysis
New Phase III data show efficacy ranging up to 100% for Bharat Biotech's inactivated vaccine, while also in India, Serum Institute sets new prices for its vaccine. Meanwhile, Russia's RDIF strikes new production deals in South Korea.
J&J, Pfizer, Russian COVID-19 Vaccines Set For Indian Approval In '21
Multiple COVID-19 vaccines, including from J&J, Pfizer and RDIF, are seen gaining approvals in India in 2021, following on from a raft of R&D, manufacturing and marketing tie-ups, as well as other developments, in the action-packed field last year.